


FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
CONNELLY ET AL.
FILING DATE
FEBRUARY 22, 2002

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

RECEIVED

SEP 27 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AM						<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

mm	AR	Bergsland, E., et al., "Shedding Old Paradigms: Developing Viruses to Treat Cancer;" <i>Journal of Clinical Oncology</i> , 20(9):2220-2222 (May 1, 2002)
mm	AS	Pecora, A., et al., "Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers;" <i>Journal of Clinical Oncology</i> , 20(9):2251-2266 (May 1, 2002)
mm	AT	Tsukuda, K., et al., "An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells: Potent Antitumoral Efficacy but No Toxicity to Normal Cell;" <i>Cancer Research</i> , 62:3438-3447 (June 15, 2002)

EXAMINER

mm

DATE CONSIDERED

3/5/09

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

BEST AVAILABLE COPY